Invitae - News & Events - Press releases

December 29, 2020 Invitae to Present at the 39th Annual J.P. Morgan Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific. Following the company presentation, management will participate in a virtual breakout session at 11:10 a.m. Eastern/8:10 a.m. Pacific. The 2021 J.P. Morgan Healthcare Conference is being held virtually via webinar. A live webcast of both the presentation and the breakout session may be accessed at the following direct link or by visiting the investors section of the company's website at ir.invitae.com . Public listeners can access an audio and slide recording of the session, which will be available shortly after the conclusion of the presentation and breakout session on the investors section of the company's website at ir.invitae.com . About Invitae Invitae Corporation (NYSE: NVTA) is a leading

December 17, 2020 Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster

- Artificial intelligence-powered technology helps bring the benefits of comprehensive clinical sequencing to patient care while maintaining exceptional accuracy and reproducibility - Invitae (NYSE: NVTA), a leading medical genetics company, today announced all patients who undergo exome testing with Invitae will receive routine case-level reanalysis of their findings every six months for at least three years. Reanalysis ensures patients' reports will be regularly updated based on new research about links between variants in their genes and their health - an essential step for people grappling with difficult-to-diagnose health problems. The expanded service will draw on Invitae's industry-leading genetic variant interpretation capabilities, which include an artificial intelligence (AI)-powered diagnosis engine and an up-to-date gene-phenotype database, and is coupled with review by a team of leading genetics experts. The combination provides accurate, reproducible, and unbiased exome

December 9, 2020 Invitae to Present New Data Supporting Genetic Testing for All Breast Cancer Patients at the 2020 San Antonio Breast Cancer Symposium

Invitae (NYSE: NVTA), a leading medical genetics company, today announced three studies demonstrating the benefits of genetic testing for all breast cancer patients, impacting treatment decisions and cancer screening for patients and their families. The studies, which will be presented at the 2020 San Antonio Breast Cancer Symposium (SABCS), add to the evidence supporting universal access to genetic information for all breast cancer patients. "It's clear that current guidelines are too restrictive and, as a result, many patients with breast cancer whose care could be improved by access to precision medicine approaches are being missed. Universal testing for all patients with solid tumor cancer, including breast cancer, can help inform treatment and improve outcomes for patients," said Robert Nussbaum, M.D., chief medical officer of Invitae. "These data, taken together with many other studies that demonstrate the utility of universal testing for cancer patients, show the time has come

November 19, 2020 New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients

- Study finds nearly 1 in 10 show genetic changes with established clinical management recommendations, potential eligibility for precision therapies and/or clinical treatment trials -
- Data presented at the National Society of Genetic Counselors Annual Conference, which will also include ceremony honoring excellence in genetic counseling patient care - Invitae (NYSE: NVTA), a leading medical genetics company, today presented study findings that show nine percent of patients with pancreatic cancer had genetic changes in DNA damage repair (DDR) genes that would make them eligible for PARP inhibitor therapy or clinical treatment trials. Despite professional guidelines that recommend testing for all pancreatic cancer patients, it remains underutilized in routine care. The study was presented at the National Society of Genetic Counselors 39 th Annual Conference. "New therapeutics have recently become available to treat pancreatic cancer for patients with certain changes in genes

November 5, 2020 Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020

- Strong results driven by comprehensive menu, customer relationships and consistent execution -
- Landmark data supporting universal genetic testing in cancer and the utility of germline and somatic testing to improve patient management published -
- Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2020. "Strategic, commercial and operating results in the third quarter continued to demonstrate the value and leverage available from our global, diversified business. These strong results are a testament to our unique combination of comprehensive menu, durable customer relationships and ability to execute," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. "We further advanced clinical understanding of the importance of genetic information with the publication of

October 28, 2020 Research Highlights Frequency of Genetic Risk Factors Among Men with Prostate Cancer, Suggests Role for Broader Screening

Data presented by Invitae (NYSE: NVTA), a leading medical genetics company, at the American Society of Human Genetics (ASHG) Virtual Meeting found one in ten men with prostate cancer harbor genetic changes linked to hereditary cancer syndromes and three-quarters of those patients met criteria for changes in cancer management or treatment based on their genetic findings. The study of more than 4,000 men with prostate cancer also found no statistical difference in the rate of cancer-causing genetic changes based on stage of disease, suggesting common criteria used to restrict testing would miss clinically important changes for many patients and their families. "These new findings provide further evidence of the strong genetic associations with prostate cancer. It's clear that we must continue to explore how we can make genetic testing more available and accessible for men with prostate cancer, which will support treatment decisions through targeted therapies, clinical trial eligibility

October 23, 2020 Invitae to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To register for the conference call and webcast, please use one of the methods below. Upon registering, each participant will be provided with call details and a registrant ID. Reminders will also be sent to registered participants via email. Online registration: http://www.directeventreg.com/registration/event/7916067 Phone registration: (888) 869-1189 or (706) 643-5902 The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website.

October 8, 2020 New Study Finds Germline Genetic Testing Detects Actionable Findings Missed by Tumor-only Sequencing

-Study suggests all cancer patients could benefit from both germline and somatic testing, utility of germline testing in identifying additional treatment options for cancer patients - Tumor-only genetic sequencing misses medically actionable genetic variants in cancer patients that germline genetic tests identify, according to a new study published this week in JAMA Network Open that included researchers from Invitae (NYSE: NVTA), a leading medical genetics company. The study also found that current clinical guidelines on who should be offered germline testing following tumor sequencing are too narrow, missing patients whose care could benefit from information about their germline genetic profile. Taken together, the study suggests the use of both tumor and germline testing provides the most complete and actionable genetic profiling to inform cancer treatment. "Tumor sequencing alone is not sufficient to provide the full genetic picture needed to inform cancer care. Our study

October 5, 2020 Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide

- World-class germline and somatic testing, liquid biopsy and tissue genomic profiling, now delivered from a single platform with unrivaled breadth and flexibility - Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing services for disease risk, therapy optimization and personalized cancer monitoring to enable precision approaches to cancer treatment. "With the addition of ArcherDX's technologies, capabilities and team, Invitae is now well positioned to accelerate the utilization of genetic information throughout a cancer patient's journey. Starting from risk profiling and diagnostic testing, moving to therapy optimization, monitoring and recurrence surveillance, Invitae can deliver the information needed to enable best-in-class personalized cancer care," said Sean George, Ph.D.,

September 11, 2020 Invitae Appoints Kimber Lockhart to its Board of Directors

- Brings expertise and leadership in scaling engineering and digital tools throughout her career as a tech entrepreneur - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Kimber Lockhart to its Board of Directors, effective September 10, 2020. "We are excited to welcome Kimber Lockhart to our board of directors, bringing expertise in scaling fast-growth businesses that will provide valuable insight as we continue to grow," said Sean George, co-founder and chief executive officer of Invitae. "Her expertise as a product, engineering and infrastructure leader, combined with her perspective on leveraging technology to improve healthcare for patients, will be a valuable addition to our board as we continue to pursue our mission to bring genetics to mainstream medicine to improve healthcare for billions of people around the world." "I'm happy to join the board of directors at Invitae at this exciting time in the company's continued

September 3, 2020 Multi-site study to evaluate the role of testing guidelines in ensuring access to genetic information for men with prostate cancer

- 1 in 9 men will be diagnosed with prostate cancer in their lifetime -
- Prostate cancer awareness month calls attention to need for research and testing - Invitae (NYSE: NVTA), a leading medical genetics company, today announced enrollment has begun for a nationwide study to better understand the role of current genetic testing guidelines in ensuring prostate cancer patients receive testing to identify clinically relevant genetic variants that can inform prognosis and support access to targeted therapies. The study is supported by Invitae and is part of the company's ongoing work to increase access to genetic information for men with prostate cancer. "Currently, germline testing guidelines for patients with prostate cancer have evolved from more than one set of NCCN guidelines and some may still find these guidelines difficult to implement in everyday practice," said Neal D. Shore, M.D., F.A.C.S. from the Carolina Urologic Research Center in Myrtle Beach, South Carolina, and

September 1, 2020 Invitae to Participate in the Morgan Stanley Virtual Global Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually participate in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference on Monday, September 14, 2020 at 4:30 p.m. Eastern / 1:30 p.m. Pacific. The live webcast of the fireside chat may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the fireside chat. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com . Contact:
Laura D'Angelo

August 4, 2020 Invitae Reports Inducement Grants Under NYSE Rule 303A.08

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted restricted stock units ("RSUs") to Kenneth D. Knight, Invitae's new Chief Operating Officer and Karthik Suri, Invitae's new Chief Digital Officer. The RSUs were granted under Invitae's 2015 Stock Incentive Plan, which was amended and restated to create an additional pool of 475,000 shares of Invitae common stock to be used exclusively for the grant of inducement awards in compliance with New York Stock Exchange Rule 303A.08 ("Rule 303A.08"). The RSUs were approved by the Board of Directors of Invitae and were made as an inducement material to each employee entering into employment with Invitae in reliance on the employment inducement exemption under Rule 303A.08. In connection with his appointment as Chief Operating Officer, Mr. Knight was granted an inducement award of 250,000 RSUs, with one-third of the RSUs vesting on each of the first three anniversaries of May 15, 2020, subject

August 4, 2020 Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020

- Introduced expanded services and support for transition to telehealth across customer types -
- Added 16 new biopharma partnerships, bringing the total number of partnership programs to more than 105 -
- Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2020. "While we experienced significant disruptions in the healthcare system due to the pandemic, we quickly established a solid recovery during the quarter. Our results highlight the strength of our operations and the benefits of our diversified menu, investments in telehealth capabilities and longstanding customer relationships, all of which position us to adapt and meet the changing needs of our customers," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. "We exited the quarter with a strong footing and

July 21, 2020 Invitae to Announce Second Quarter 2020 Financial Results on August 4, 2020

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. To register for the conference call and webcast, please use one of the methods below. Upon registering, each participant will be provided with call details and a registrant ID. Reminders will also be sent to registered participants via email. Online registration: http://www.directeventreg.com/registration/event/5882896 Phone registration: (888) 869-1189 or (706) 643-5902 The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website.

June 22, 2020 Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology

- Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring -
- Provides unrivaled breadth and flexibility for clinicians, democratizing the use of genetics in routine care worldwide -
- Hosting webcast for investors today at 5:00 a.m. PT / 6:00 a.m. MT / 8:00 a.m. ET - Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology. The combined company will be poised to transform care for cancer patients, accelerating adoption of genetics through the most comprehensive suite of products and services available.

June 11, 2020 Recent Research And New Multidisciplinary Framework For Genetic Testing In Prostate Cancer Supports Broader Use Of Panels, Testing In Early Stage Disease

- Research highlights frequency of clinically important genetic variants across all stages of prostate cancer - New recommendations from a large, multidisciplinary consensus conference published this week in the Journal of Clinical Oncology suggest expanding use of genetic testing to guide treatment for men with prostate cancer, including the use of panel testing and testing patients with early stage disease. Taken together with research recently presented by Invitae (NYSE: NVTA), a leading genetics company, the publications underscore the utility of increased access to genetic testing for men with prostate cancer across all stages of disease. Invitae was among the non-voting sponsors of the conference, which gathered more than 100 experts across a number of specialties with the goal of developing recommendations for how clinicians can use genetic testing to help patients benefit from precision medicine approaches to prostate cancer. "Inherited prostate cancer is starting to get the

May 28, 2020 Invitae to Present at the William Blair 40th Annual Growth Stock Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually present at the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020 at 9:20 a.m. Central / 7:20 a.m. Pacific. The live webcast of both the presentation may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcasts will be available shortly after the conclusion of the presentation. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com . Contact:
Laura D'Angelo
i r@invitae.com
(628) 213-3369

May 7, 2020 Invitae makes it easier for consumers to access medical genetic tests in Canada

Invitae (NYSE: NVTA), a leader in medical genetics, today announced the expansion of online ordering for its high-quality medical genetic tests to Canada. Through the service, Canadians can access genetic testing recommended in early pregnancy as well as cancer risk assessments using telehealth guidance and kits that can be shipped to and from home. The service provides easier access to the same high-quality, medical genetic testing that experts use and trust worldwide during a time when healthcare visits are being delayed and wait times to see clinicians are growing. "Genetic information can help people make better, more informed decisions about their health, for example helping a woman understand her risk of giving birth to a child with a genetic disorder or of developing breast cancer. Too often people find that medical testing is expensive or difficult to obtain," said Robert Nussbaum, M.D., chief medical officer of Invitae. "We are making it easier for people to get affordable,

May 5, 2020 Invitae Reports More Than $64 Million in Revenue Driven by More Than 154,000 Samples Accessioned in the First Quarter of 2020

- Increased quarterly revenue by 58% and volume by nearly 64% year-over-year -
- Launched enhanced capabilities to support telemedicine solutions -
- Implemented various actions to reduce cash burn in 2020 -
- Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2020. "We started the year with a very strong quarter, delivering record growth in volume and first quarter revenues and giving us strong momentum as we began experiencing impacts from the pandemic. As healthcare has shifted, we have been able to quickly leverage our pre-existing strengths, notably our telehealth offerings and our ability to deliver genetic testing remotely," said Sean George, co-founder and chief executive officer of Invitae. "Looking ahead, our investments in diversified products, services, technologies and

April 21, 2020 Invitae to announce first quarter 2020 financial results on May 5, 2020

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2020 financial results on Tuesday, May 5, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 324-3683 for domestic callers and (509) 844-0959 for international callers, and the Conference ID for both is 9557177. Please note after dialing in, you will be prompted to enter the Conference ID and then the pound "#" sign to enter the call. The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. Following prepared remarks, management will respond to questions from investors and

April 7, 2020 Invitae launches enhanced capabilities to support telemedicine

- Clinical chatbot Gia offers new tools for OB/GYNs, oncologists, genetic counselors and other clinicians who order genetic testing - Invitae (NYSE: NVTA), a leading medical genetics company today announced new tools to help obstetrician/gynecologists, oncologists, genetic counselors and other clinicians who order genetic tests via telemedicine for women and couples early in pregnancy and for patients with cancer. Invitae's advanced clinical chatbot, Gia, provides an end-to-end telemedicine genetic testing framework that helps identify patients who need germline genetic testing. The need for streamlined solutions to patient education and intake has been growing, becoming more acute during the current pandemic. Clinicians are rapidly turning to telemedicine to provide continuity of care for patients who face disruptions to clinic visits, such as women who are newly pregnant or patients with cancer. Adapting to remote care requires tools that make it easier to replace tasks that were

April 6, 2020 Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering

Invitae Corporation (NYSE: NVTA) today announced the closing of its underwritten public offering of 20,444,444 shares of its common stock, including 2,666,666 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, at the public offering price of $9.00 per share. As a result of the underwriters' option exercise, the aggregate gross proceeds to Invitae from the offering, before deducting underwriting discounts and commissions and other offering expenses, was approximately $184.0 million. J.P. Morgan Securities LLC and Cowen and Company, LLC acted as the book-running managers for the offering. An automatic shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on March 4, 2019. A copy of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long

April 1, 2020 Invitae Announces Pricing of Public Offering of Common Stock

Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 17,777,778 shares of its common stock at a price to the public of $9.00 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $160.0 million. The offering is expected to close on or about April 6, 2020, subject to customary closing conditions. In addition, Invitae has granted the underwriters a 30-day option to purchase up to an additional 2,666,666 shares of its common stock at the public offering price, less underwriting discounts and commissions. J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as the book-running managers for the offering. An automatic shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on March 4, 2019. A

April 1, 2020 Invitae Announces Proposed Public Offering of Common Stock

Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as the book-running managers for the offering. An automatic shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and became effective on March 4, 2019. A copy of the preliminary

March 23, 2020 Invitae and Muscular Dystrophy Association (MDA) Expand Access to No-Charge Genetic Testing in the U.S. and Canada

- MDA to offer Invitae's Detect Muscular Dystrophy program in 150 care centers - Invitae (NYSE: NVTA), a leading medical genetics company today announced its partnership with the Muscular Dystrophy Association (MDA) to offer sponsored, no-charge genetic testing to patients through the Detect Muscular Dystrophy program in MDA's care center network, a network of clinics at more than 150 of the nation's top healthcare institutions. Research has shown no-charge testing programs help increase utilization of genetic testing, which can shorten the time to diagnosis by as much as two years in some conditions. Accurate diagnoses enable clinicians to focus on providing disease-specific care sooner, helping reduce costs and improve outcomes. "Muscular dystrophy consists of many disorders with overlapping symptoms that often make diagnosis more challenging. Genetic testing can help accelerate diagnosis and treatment of conditions such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy

March 10, 2020 Invitae Acquires Diploid, Maker of Artificial-Intelligence Engine to Enable Clinical Diagnosis Using Whole Genome Sequencing in Minutes

- Adds to Invitae's competitive advantage by providing rapid answers to patients while further reducing the cost of genetic testing at scale -
- Hosting conference call and webcast today at 2:00 pm Pacific / 5:00 pm Eastern -
- Inducement Grants Under NYSE Rule 303A.08 for Employees - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced today the acquisition of Diploid, a privately held Belgian company that developed Moon, artificial intelligence (A.I.) software capable of diagnosing genetic disorders in minutes based on next-generation sequencing data and patient information. The addition of Moon to Invitae's state-of-the-art variant interpretation infrastructure extends its ability to quickly and efficiently turn large amounts of genetic data and phenotypic information into actionable reports for patients and clinicians. "The addition of Diploid's software to Invitae's best-in-class variant interpretation platform will provide an immediate

March 10, 2020 Invitae to Acquire YouScript and Genelex to Make it Easier to Use Pharmacogenetic Information at the Point of Care

- Unique combination of pharmacogenetic information with sophisticated, EMR-integrated software has been shown to reduce risk and improve outcomes -
- Hosting conference call and webcast today at 2:00 pm Pacific / 5:00 pm Eastern - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced it has entered into definitive agreements to acquire YouScript, a privately held clinical decision support and analytics platform, and Genelex, a privately held pharmacogenetic testing company, to bring best-in-class pharmacogenetic testing, and robust, integrated clinical decision support to Invitae. Pharmacogenetic testing evaluates genetic variations that can impact how an individual responds to prescription medication. "Adding pharmacogenetics to Invitae's services enables us to offer greater value to our existing customers and helps us expand into new customer types and clinical areas," said Sean George, co-founder and chief executive officer of Invitae.

March 3, 2020 Invitae to Present at Oppenheimer's 30th Annual Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co founder and chief executive officer of Invitae, will present at Oppenheimer's 30th Annual Healthcare Conference on Tuesday, March 17, 2020 at 1:00 p.m. Eastern in New York City. The live webcast of both the presentation and the breakout session may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcasts will be available shortly after the conclusion of the presentation and breakout session. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com. Contact:

February 25, 2020 Invitae to Present at the Cowen and Company's 40th Annual Health Care Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Cowen and Company's 40 th Annual Health Care Conference on Monday, March 2, 2020 at 2:50 p.m. Eastern in Boston, Massachusetts. The live webcast of both the presentation and the breakout session may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcasts will be available shortly after the conclusion of the presentation and breakout session. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website

February 20, 2020 Invitae to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 9:30 a.m. Eastern in New York City. The live webcast of both the presentation and the breakout session may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcasts will be available shortly after the conclusion of the presentation and breakout session. About Invitae Invitae Corporation (NYSE: NVTA) is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.

February 19, 2020 Invitae Reports $216.8 Million in Annual Revenue Driven by More Than 482,000 Samples in 2019

- Increased annual revenue by approximately 47% and annual volume by nearly 60% year-over-year -
- Issued 2020 guidance of more than 725,000 samples accessioned and more than $330 million in revenue, reflecting a more than 50% annual growth in both volume and revenue -
- Hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the fourth quarter and full year ended December 31, 2019. "In 2019, we delivered another year of extraordinary growth, both in the U.S. and internationally. We expanded our customer base and saw strong re-order rates among new accounts. We also made it easier to access our testing, both through traditional payers and via unique partnership programs," said Sean George, co-founder and chief executive officer of Invitae. "We enter 2020 with momentum and a unique business model that we believe is well-positioned

February 5, 2020 Invitae to announce fourth quarter and full year 2019 financial results on February 19, 2020

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2019 financial results on Wednesday, February 19, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 2782984. The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. We encourage our shareholders and those representing them

January 12, 2020 Invitae preliminary 2019 financial results demonstrate strong momentum with nearly 60% growth in test volume and more than 45% growth in revenue year-over-year

- Accessioned more than 482,000 samples and generated approximately $216 million in revenue in 2019 -
- Issues 2020 guidance of more than 725,000 samples accessioned and more than $330 million in revenue, reflecting a more than 50% annual growth in both volume and revenue - Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2019 results, driving strong growth in volume and revenues, signaling continued momentum going into 2020. The company accessioned more than 482,000 samples and generated approximately $216 million in revenue in 2019. The company also announced 2020 guidance of more than 725,000 samples accessioned and more than $330 million in revenue, reflecting a more than 50% annual growth in both volume and revenue. Invitae has now provided in-depth medical genetic sequencing for more than one million patients since launch, including more than 750,000 in the past two years. "Invitae is proving that genetics is a

January 8, 2020 Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy

- Biogen, Encoded Therapeutics, Neurogene, Praxis Precision Medicines and PTC Therapeutics join founders BioMarin and Invitae to expand access for children under eight -
- Innovative program may shorten the diagnostic odyssey for children who experience unprovoked seizures - Today BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Invitae Corporation (NYSE: NVTA) announced that Biogen (NASDAQ: BIIB), Encoded Therapeutics, Neurogene, Praxis Precision Medicines and PTC Therapeutics joined Behind the Seizure ® , an innovative, cross-company collaboration that aims to provide faster diagnosis for young children with epilepsy. The program will also be expanded to make no-charge testing available for healthcare providers to order for any child under the age of eight who has an unprovoked seizure. "Behind the Seizure is one of the longest-running cross-company collaborations aimed at increasing access to genetic testing. It has been shown to decrease time to diagnosis for children

Press releases

FORWARD-LOOKING STATEMENTS

Investor Toolkit

Feature Presentation

Email Alerts

Investor Contact


Email Address:	*



Enter the code shown above.
*